HealthDay News — For patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), obecabtagene autoleucel (obe-cel), an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T ...

In a cohort of 94 patients with morphologic disease, overall remission occurred in 77% of those who received at least one infusion of obe-cel, with complete remission (CR) in 55% and CR with ...